The light-activated drug, Verteporfin, inhibits the growth of glioblastoma cells by downregulating YAP-TEAD-associated downstream signaling molecules such as c-MYC, CTGF, and CYR6157. The gene discussed is CCN2; the disease is glioblastoma.